[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
Biró K, Küronya Z.
Biró K, et al.
Magy Onkol. 2010 Dec;54(4):369-76. doi: 10.1556/MOnkol.54.2010.4.11.
Magy Onkol. 2010.
PMID: 21163768
Free article.
Review.
Hungarian.
In cytokine refractory patients, sorafenib, when patients have progressed on a tyrosine kinase inhibitor everolimus is the agent of choice. Biro K, Kuronya Z. Recent advancements in the treatment of renal cell carcinoma - focus on international guidelines....
In cytokine refractory patients, sorafenib, when patients have progressed on a tyrosine kinase inhibitor everolimus is the agent of choice. …